Paul A Bunn Selected Research

Paul A Bunn Research Topics

Disease

83	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 02/2002
63	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2002
59	Neoplasms (Cancer) 01/2022 - 02/2002
9	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 04/2002
6	Disease Progression 01/2022 - 12/2003
6	Adenocarcinoma 01/2018 - 02/2002
5	Adenocarcinoma of Lung 10/2020 - 02/2015
5	Neoplasm Metastasis (Metastasis) 11/2018 - 03/2002
4	Breast Neoplasms (Breast Cancer) 01/2018 - 02/2002
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2012 - 02/2002
3	Febrile Neutropenia 09/2006 - 05/2004
3	Prostatic Neoplasms (Prostate Cancer) 08/2005 - 04/2002
3	Neutropenia 11/2004 - 05/2004
2	Brain Neoplasms (Brain Tumor) 11/2018 - 12/2013
2	Sarcoma (Soft Tissue Sarcoma) 02/2015 - 09/2012
2	Chronic Obstructive Pulmonary Disease (COPD) 11/2007 - 05/2006
2	Carcinoma (Carcinomatosis) 01/2007 - 07/2002
2	Carcinogenesis 12/2005 - 06/2002
2	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 10/2005 - 10/2003
2	Mesothelioma 06/2002 - 04/2002
1	COVID-19 01/2022
1	Intestinal Volvulus (Volvulus) 01/2020

Drug/Important Bio-Agent (IBA)

37	ErbB Receptors (EGF Receptor)IBA 01/2020 - 02/2002
24	Tyrosine Kinase InhibitorsIBA 01/2020 - 02/2002
18	Gefitinib (Iressa)FDA Link 01/2018 - 02/2002
15	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2002
13	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2002
11	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 04/2002
10	Pemetrexed (MTA)FDA Link 01/2017 - 04/2002
10	Docetaxel (Taxotere)FDA Link 10/2007 - 02/2002
9	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2017 - 12/2006
8	Carboplatin (JM8)FDA LinkGeneric 01/2018 - 04/2002
7	Pharmaceutical PreparationsIBA 12/2018 - 04/2002
6	CrizotinibIBA 11/2018 - 12/2012
5	Monoclonal AntibodiesIBA 01/2018 - 02/2002
5	Paclitaxel (Taxol)FDA LinkGeneric 09/2011 - 01/2003
5	sulindac sulfone (exisulind)IBA 10/2007 - 02/2002
5	Gemcitabine FDA Link 11/2005 - 04/2002
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 11/2002
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2006 - 02/2002
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2020 - 12/2006
3	Phosphotransferases (Kinase)IBA 01/2018 - 01/2013
3	Etoposide (VP 16)FDA LinkGeneric 01/2018 - 05/2006
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 06/2002
3	human ERBB2 proteinIBA 11/2017 - 02/2015
3	Anaplastic Lymphoma KinaseIBA 03/2016 - 09/2012
3	Messenger RNA (mRNA)IBA 06/2014 - 05/2006
3	Cetuximab (Erbitux)FDA Link 07/2008 - 01/2005
3	Biological ProductsIBA 05/2006 - 08/2003
3	Bradykinin Receptor AntagonistsIBA 08/2005 - 05/2002
3	Trastuzumab (Herceptin)FDA Link 06/2002 - 02/2002
2	PlatinumIBA 01/2022 - 10/2007
2	Formaldehyde (Formol)FDA Link 10/2020 - 02/2013
2	osimertinibIBA 01/2020 - 03/2017
2	KIR ReceptorsIBA 01/2018 - 12/2016
2	taxaneIBA 01/2018 - 03/2002
2	TankyrasesIBA 03/2017 - 08/2012
2	Volatile Organic CompoundsIBA 08/2013 - 07/2012
2	GoldIBA 08/2013 - 07/2012
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2013 - 01/2004
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 02/2013 - 06/2011
2	Bevacizumab (Avastin)FDA Link 01/2013 - 03/2007
2	Epidermal Growth Factor (EGF)IBA 01/2009 - 05/2005
2	Cadherins (E-Cadherin)IBA 06/2007 - 01/2006
2	Metalloproteases (Metalloproteinases)IBA 08/2005 - 12/2002
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 05/2003 - 03/2002
2	Cyclic GMPIBA 05/2003 - 03/2002
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2002 - 04/2002
2	BradykininIBA 12/2002 - 04/2002
2	Drug CombinationsIBA 09/2002 - 06/2002
2	AntimetabolitesIBA 06/2002 - 04/2002
2	Antineoplastic Agents (Antineoplastics)IBA 05/2002 - 02/2002
2	NeuropeptidesIBA 05/2002 - 04/2002
2	EnzymesIBA 05/2002 - 03/2002
1	VaccinesIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	ParaffinIBA 10/2020
1	Pioglitazone (Actos)FDA Link 10/2019
1	ThiazolidinedionesIBA 10/2019
1	Methylnitronitrosoguanidine (MNNG)IBA 01/2019
1	Proto-Oncogene Proteins c-metIBA 01/2019
1	Carcinoembryonic AntigenIBA 01/2018
1	eribulin FDA Link 01/2018
1	Tumor Biomarkers (Tumor Markers)IBA 01/2018
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018
1	Topotecan (Hycamtin)FDA LinkGeneric 11/2017
1	Liposomes (Liposome)IBA 11/2017
1	Aurora KinasesIBA 10/2016
1	Immune Checkpoint ProteinsIBA 09/2016
1	MAP Kinase Kinase 1IBA 02/2015

Therapy/Procedure

51	Therapeutics 01/2022 - 04/2002
20	Drug Therapy (Chemotherapy) 12/2014 - 02/2002
9	Chemoprevention 10/2019 - 02/2002
5	Radiotherapy 01/2018 - 09/2004
3	Adjuvant Chemotherapy 06/2007 - 09/2004
2	Neoadjuvant Therapy 03/2019 - 12/2018
2	Immunotherapy 12/2018 - 01/2016
2	Combination Drug Therapy (Combination Chemotherapy) 03/2016 - 08/2005
2	Aftercare (After-Treatment) 06/2007 - 05/2003
1	Lymph Node Excision (Lymph Node Dissection) 07/2015